NIPT

NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Mercredi, mai 15, 2024
Campaign, Insurance, Patient, Hindenburg Research, Genetic testing, News, DSM-IV codes, FDA, The New York Times, Telephone, Safety, Oportunidades, Marketing, Chromosome, NIPT, Growth, Complaint, Fetus, P.C, Communication, Panorama, NTRA, Cryptocurrency

Our investigation concerns whether the board of directors of Natera have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Natera have breached their fiduciary duties to the company.
  • Natera, a Delaware corporation with principal executive offices in Austin, Texas, offers genetic testing in the areas of women’s health, oncology, and organ health.
  • Among other things, The New York Times reported that Natera’s positive results for several genetic disorders were incorrect more than 80 percent of the time.
  • In addition, the FDA advised health care providers that they should not rely on NIPT results alone to diagnose chromosomal abnormalities or disorders.

$12.85+ Bn Non-Invasive Prenatal Testing (NIPT) Markets - Global and Regional Market Analysis, Forecast, and Competition Landscape 2023-2024 & 2033 - ResearchAndMarkets.com

Retrieved on: 
Jeudi, mai 23, 2024
Biotechnology, Genetics, Health, NGS, Insurance, Chromosome, DNA, Trisomy, Region, BGI Group, Amniocentesis, Risk, Maternal death, Diagnosis, Ecosystem, DSM-IV codes, Safety, NIPT, Down syndrome, Blood, Prenatal care, Growth, Research, Incidence, Workflow, Genomics, Nucleic acid thermodynamics, Labcorp, PCR

The NIPT market in the Asia-Pacific region is witnessing significant growth of 15.43% in the forecast period, marked by increasing number of market players, and shifting healthcare landscape.

Key Points: 
  • The NIPT market in the Asia-Pacific region is witnessing significant growth of 15.43% in the forecast period, marked by increasing number of market players, and shifting healthcare landscape.
  • In 2022, Asia-Pacific accounted for a share of 19.50% of the global NIPT market.
  • The global NIPT market is characterized by intense competition, as established entities and emerging players compete for a share of the market.
  • The global NIPT market (by method) was dominated by the cfDNA segment in FY2022.

Global Prenatal Testing Market Report 2024: Historical Revenue Data for 2021-2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, mai 3, 2024
Baby, Maternity, Health, Consumer, Other Health, Insight, Noninvasive prenatal testing, Pregnancy, DSM-IV codes, Research, Genetic testing, Labcorp, Government, NIPT, Amniocentesis, ESG, Thermo Fisher Scientific, Maternal death, Chromosome, Illumina, Inc., Biomarker

The "Global Prenatal Testing Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Prenatal Testing Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The scope of the prenatal testing market is extensive and continually evolving, reflecting the dynamic landscape of technologies and methodologies employed to assess fetal health during pregnancy.
  • This market is characterized by its global reach, with varying levels of adoption and accessibility across different regions.
  • The report covers geographic regions in detail, so companies interested in expanding their geographic reach will also find this helpful study.

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

Retrieved on: 
Mercredi, mai 1, 2024
Health, Consumer, Women, Genetics, Baby, Maternity, Clinical Trials, Biotechnology, Fetus, Nucleic acid thermodynamics, Gamma globulin, Episcopal conference, American College, NTRA, Laboratory, RHD (gene), Anemia, Risk, Pregnancy, Blood, Northwell Health, Quality, Genetic testing, Obstetrics, DNA, SNP, ACOG, ASHG, NIPT, Patient, Human genetics, Society, Physician, Antibody, Panorama, Dietary supplement

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.
  • This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg).
  • Natera’s test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including complex pseudogene and RhD-CE-D hybrid variants.
  • The vast majority of other NIPT laboratories do not offer fetal RhD assessment, which makes it a key differentiator in addition to Natera’s core SNP-based technology.

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

Retrieved on: 
Lundi, avril 22, 2024
Research, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Other Science, Science, Oncology, Nucleic acid thermodynamics, NTRA, Investment, Publication, Colorectal cancer, Genetic testing, SMART, DNA, NIPT, Patient, Kidney transplantation, NEJM, Clinical trial, ProActive, Chronic kidney disease, Cohort (statistics), Pharmaceutical industry

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.
  • Landmark cutting-edge science and clinical trial data based on Natera’s suite of products have been published in top journals, such as Science, Nature, Nature Medicine, and New England Journal of Medicine (NEJM).
  • “When it comes to transforming patient care, high-quality science and data drive everything,” said Alexey Aleshin, M.D., chief medical officer & general manager of oncology at Natera.
  • We remain committed to generating evidence that supports the real-world impact of our innovations.”

China Non-Invasive Prenatal Testing (NIPT) Market to Surge to $1,083 Million by 2032 - ResearchAndMarkets.com

Retrieved on: 
Jeudi, mars 28, 2024
Health, Consumer, Baby, Maternity, General Health, Pharmaceutical, Biotechnology, NIPT, Growth, Dietary supplement

The "China Non-Invasive Prenatal Testing Market Growth, Share, Size, Trends and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Non-Invasive Prenatal Testing Market Growth, Share, Size, Trends and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering.
  • The report offers an exhaustively researched overview of the Chinese non-invasive prenatal testing market with up-to-date data on the current market landscape and a forecast that stretches to 2032.
  • A detailed overview of the critical factors driving the expansion of the China non-invasive prenatal testing market is included in the report.
  • What is the total market size and forecast (until 2032) for the China non-invasive prenatal testing market?

Igentify Launches New NIPT and Pharmacogenomics Offerings

Retrieved on: 
Mardi, mars 5, 2024
Technology, Science, Family, Genetics, Consumer, Clinical Trials, Biotechnology, Health, Health Technology, Apps, Applications, Research, Software, Other Health, Internet, Parenting, Pharmaceutical, Baby, Maternity, ACOG, NIPT, ECS, Workflow

Igentify , a digital health company alleviating bottlenecks in the genetic testing process, announced the launch of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform.

Key Points: 
  • Igentify , a digital health company alleviating bottlenecks in the genetic testing process, announced the launch of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform.
  • This new roll-out comes in addition to their Expanded Carrier Screening (ECS) offering.
  • The NIPT workflow includes a patient web-app that facilitates all aspects of patient intake, including an ACOG-compliant consenting process using Igentify’s proprietary video technology to create highly personalized educational videos for each patient.
  • “We are thrilled to expand the accessibility of our platform with programs focused on non-invasive prenatal testing and pharmacogenomics,” said Elliott Greenspan, Chief Innovation Officer and Co-founder of Igentify.

Molecular Diagnostics in Oncology, Genetic/Inherited Diseases and NIPT 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Lundi, janvier 29, 2024
Health, Oncology, ISH, NGS, DSM-IV codes, Research, Molecular diagnostics, IVD, Knowledge, NIPT, Cancer, Woman, Medicine, Risk, FISH, Recurrence, Laboratory, FDA, Biomarker, Diagnosis, PCR, Inherit, Segment, Chromosome, Gene expression, Medical imaging

The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • In addition, the fields of rare inherited/ genetic diseases and NIPT have become areas of new breakthroughs in healthcare.
  • These and other technologies and applications in oncology, rare inherited/ genetic disease, and NIPT molecular diagnostic testing are covered in the report.
  • The report contains detailed market data on the following IVD segments for their use in molecular testing:
    Molecular Diagnostics in Oncology Market by Segment, 2023-2028

Identifai-Genetics Launches Its First U.S. Clinical Trial, Led by Professor Ronald Wapner

Retrieved on: 
Jeudi, janvier 11, 2024
Woman, Columbia, Assistant, Associate, DNA, Gynaecology, Birth, NIPT, Partnership, AI, Genetics, TEL, Pregnancy, Disease, Genetic counseling, Prevalence, Columbia University, Obstetrics, Anomaly, Parent, Clinical trial, Research, Fetus, Trial of the century

Identifai's platform and diagnostic tools enable early detection of the whole spectrum of fetal genetic disorders in an accessible, cost-effective and risk-free manner.

Key Points: 
  • Identifai's platform and diagnostic tools enable early detection of the whole spectrum of fetal genetic disorders in an accessible, cost-effective and risk-free manner.
  • Identifai's US clinical study is aimed at demonstrating the performance and effectiveness of the company's novel technology in real-world scenarios within the United States.
  • The principal investigator in the study is world-renowned Professor Ronald J. Wapner, Director of Reproductive Genetics and Professor of Obstetrics and Gynecology at Columbia University Irving Medical Center.
  • This study marks a critical milestone in transforming Identifai's technology into a clinical offering accessible to millions of women in the US and across the globe".

Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend

Retrieved on: 
Lundi, janvier 8, 2024
Pseudogene, RNA, Biomedical Research, Protein, NIPT, Antibody, Telecommunications, Workflow, Research, DNA, SAN, Methylation, Biomarker, Infection, BioLegend, Fine chemical

This marks the first instance of an early access version of RAPTOR with Pleno’s groundbreaking multi-omic readout technology called Hypercoding ™ verified outside of its development lab.

Key Points: 
  • This marks the first instance of an early access version of RAPTOR with Pleno’s groundbreaking multi-omic readout technology called Hypercoding ™ verified outside of its development lab.
  • The RAPTOR instrument platform utilizes Hypercoding to detect these biomarkers rapidly and efficiently at a sample throughput that is scalable from a couple dozen samples to 96.
  • To this end, Pleno and BioLegend have collaborated to integrate their technologies, facilitating a streamlined approach for customers to enable multi-omic content.
  • “We are extremely proud to see the first of our RAPTOR instruments leave the nest,” said Pieter van Rooyen, founder and CEO of Pleno.